Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide. It offers Pradefovir, Posaconazole, Voriconazole, CAPVAXIVE, NOXAFIL, MenFive, and ZELSUVMI for infectious disease; EVOMELA and KYPROLIS for multiple myeloma; FILSPARI, a dual endothelin and angiotensin II receptor antagonist for immunoglobulin A nephropathy; Ohtuvayre for respiratory disease; PNEUMOSIL, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia in children; and QARZIBA to treat neuroblastoma. The company also provides Teriparatide injection product for osteoporosis; RYLAZE, a recombinant erwinia asparaginase for acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes in adults and children aged 8 years and older with Stage 2 T1D; and VAXNEUVANCE for the prevention of invasive disease caused by streptococcus pneumoniae serotypes. In addition, it offers Duavee for menopause; Frovatriptan to treat Neurology; FYCOMPA and SESQUIENT for CNS; LYTENAVA to treat Opthamology; MEKINIST for cardiology; MINNEBRO for metabolic disease; Nexterone, a captisol-enabled formulation of amiodarone; VEKLURY, an antiviral treatment for COVID-19; and Viviant for osteoporosis. Further, the company develops ACLX-002, Ciforadenant, UGN-301, Viright, JZP341, MB07133, BOT/BAL, and Lasofoxifene for oncology; Ensifentrine for respiratory disease; QTORIN for rare disease; Sparsentan for kidney disease; VK2809 for hepatology; ANEB-001 for acute cannabinoid intoxication; CE-furosemide for cardiology; CE-Meloxicam for neurology; V117, CX2101A, and Sitavig for infectious disease; REV-0100, OPT-302, and Reproxalap for opthamology; Vilazodone and Topiramate Injection for CNS; VK0214 for Rare Disease; and VK5211 for musculoskeletal disorder. The company was incorporated in 1987 and is based in Jupiter, Florida.

Ligand Pharmaceuticals Incorporated

In a report released today, Annabel Samimy from Stifel Nicolaus maintained a Buy rating on Ligand Pharma, with a price target of $220.00. According...

Stifel Nicolaus Reaffirms Their Buy Rating on Ligand Pharma (LGND)

Oppenheimer analyst Trevor Allred maintained a Buy rating on Ligand Pharma today and set a price target of $250.00. The company’s shares opened tod...

Current Quarter	$0.63	Next Quarter	$0.62
Current Year	$-0.51	Next Year	$4.67
QoQ Growth	-1.6%	YoY Growth	+1015.7%
3Y EPS CAGR	-28.1%	Target Price	$225.00
Consensus	Buy	Upside	+12.9%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	LGND	$199.23	+0.10%	264.60K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	LGND	$199.23	+0.1%	264.60K
3
4
5
6

LGND

LGND

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get Ligand Pharmaceuticals Incorporated Data in Excel

Get Ligand Pharmaceuticals Incorporated Data in Excel